Drug updated on 4/17/2024
| Dosage Form | Injection (intravenous: 30 mg/100 mL); Suspension (oral: 105 mg/5 mL) |
| Drug Class | Free radical scavengers |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- To treat patients with amyotrophic lateral sclerosis (ALS).
Summary
- Edaravone (Radicava) is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).
- A total of 6 systematic reviews and meta-analyses were reviewed, providing insights into the efficacy and safety profile of edaravone in treating ALS.
- The studies included in these documents suggest that edaravone improves survival rates at 18, 24, and 30 months without any significant adverse effects among ALS patients.
- However, it was noted across multiple studies that edaravone does not significantly affect functional outcomes in ALS patients despite improving survival rates.
- Some research also suggests potential benefits from using edaravone to treat ischemic stroke by reducing neurological deficits and mortality; however more randomized trials are needed outside Asia to confirm this hypothesis.
- Despite some promising results regarding its use for acute intracerebral hemorrhage onset within seven days, current evidence is insufficient to support routine use of Radicava due to lack of data on long-term functional outcomes as well as overall poor quality and high heterogeneity among existing trials.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Radicava (edaravone) Prescribing Information. | 2022 | Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ |